Rikoon Group LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 7,799 shares of the biopharmaceutical company’s stock after selling 998 shares during the quarter. Rikoon Group LLC’s holdings in Gilead Sciences were worth $488,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in GILD. Advisors Preferred LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at $31,000. Legacy Financial Advisors Inc. boosted its stake in shares of Gilead Sciences by 361.3% in the 4th quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 383 shares in the last quarter. We Are One Seven LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at $37,000. Larson Financial Group LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at $38,000. Finally, Jackson Grant Investment Advisers Inc. boosted its stake in shares of Gilead Sciences by 56.9% in the 4th quarter. Jackson Grant Investment Advisers Inc. now owns 717 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 260 shares in the last quarter. 77.76% of the stock is owned by institutional investors and hedge funds.
NASDAQ:GILD opened at $65.02 on Friday. Gilead Sciences, Inc. has a 52 week low of $60.32 and a 52 week high of $82.71. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.36 and a quick ratio of 3.29. The firm has a market cap of $85.04 billion, a P/E ratio of 10.57, a PEG ratio of 4.14 and a beta of 1.19.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing the Zacks’ consensus estimate of $1.70 by ($0.26). Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.52 billion. During the same quarter in the prior year, the company earned $1.78 earnings per share. The company’s quarterly revenue was down 2.6% compared to the same quarter last year. Equities research analysts expect that Gilead Sciences, Inc. will post 6.23 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Shareholders of record on Friday, March 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 annualized dividend and a yield of 3.88%. Gilead Sciences’s dividend payout ratio is 37.07%.
In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $71.20, for a total value of $3,560,000.00. Following the completion of the transaction, the director now directly owns 2,877,762 shares in the company, valued at approximately $204,896,654.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gayle E. Wilson sold 19,068 shares of the company’s stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the completion of the transaction, the director now owns 143,567 shares of the company’s stock, valued at $9,630,474.36. The disclosure for this sale can be found here. 1.16% of the stock is currently owned by corporate insiders.
A number of equities research analysts have recently issued reports on GILD shares. Guggenheim initiated coverage on shares of Gilead Sciences in a research note on Monday, December 17th. They issued a “buy” rating and a $86.00 price objective for the company. BidaskClub upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Tuesday, December 4th. Raymond James reiterated a “buy” rating on shares of Gilead Sciences in a report on Thursday, November 1st. Mizuho set a $94.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Thursday, November 1st. Finally, Citigroup reiterated a “buy” rating and set a $100.00 price target on shares of Gilead Sciences in a report on Tuesday, February 5th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $82.56.
TRADEMARK VIOLATION WARNING: This story was published by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://transcriptdaily.com/2019/03/01/rikoon-group-llc-cuts-holdings-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
See Also: What is insider trading?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.